Amgen highlights obesity pipeline progress, shares track pharma peers
26.06.2026 - 13:13:45 | ad-hoc-news.de
By Christina Vogel, Background & Management desk. Reviewed prior to publication on 2026-06-26, 13:13.
Amgen Inc. (US0311621009) remains in focus for NASDAQ investors as the group advances its obesity and cardiovascular drug pipeline alongside steady cash returns. Sector peers like Eli Lilly and Novo Nordisk frame the valuation debate around obesity-driven growth.
What recent reports highlight
Analyst and media commentary over the past days has emphasized Amgen's experimental obesity drug MariTide (AMG 133), which targets the same broad market as Lilly's Zepbound and Novo Nordisk's Wegovy, though with a distinct mechanism and dosing profile according to company presentations and recent coverage. A Reuters overview of obesity-drug competition underlines investor attention on potential long-acting candidates.
In parallel, large-cap pharma sector pieces from U.S. market commentators note that Amgen still derives a substantial share of revenue from mature products such as Enbrel and Prolia while investing heavily in cardiovascular assets like Repatha and new oncology candidates. A recent Wall Street Journal discussion of big-pharma valuations points out that pipelines beyond obesity remain key to justifying premiums for the sector.
Analyst consensus and growth drivers
According to consensus data compiled by MarketScreener, a majority of covering analysts currently rate Amgen stock as Buy or Outperform, with only a small minority on Hold or Sell, reflecting confidence in pipeline depth and cash-generation capacity. The same compilation shows a double-digit upside potential to the average 12-month price target compared with the latest trading price, based on data refreshed this week. MarketScreener's Amgen consensus page details the distribution of ratings and targets.
U.S. broker research cited in financial media highlights three pillars of the Amgen investment case: execution on the obesity franchise, lifecycle management of legacy immunology drugs, and integration of acquired assets such as Horizon Therapeutics, which broaden exposure to rare diseases. Recent banking notes also underscore Amgen's record of dividend growth and share repurchases, which support total shareholder return even when revenue growth is modest in some years.
All news and analysis on the Amgen shares
Follow additional headlines, background pieces and regulatory disclosures on Amgen to track how new trial data, acquisitions and guidance changes feed into the stock's long-term story.
What the company sells
Amgen generates most of its revenue from biologic therapies for serious illnesses, with key products including autoimmune drug Enbrel, bone-health medicine Prolia, cholesterol-lowering therapy Repatha and a growing roster of oncology and rare-disease treatments acquired or developed in-house. The pipeline spans obesity, inflammation and cardiovascular disease.
Where the stock trades today
Amgen shares most recently traded on NASDAQ at around 352.82 USD, based on data from Investing.com with pricing as of 2026-06-25, 21:40 UTC.
Amgen in numbers at a glance
- Company: Amgen Inc.
- ISIN: US0311621009
- WKN: 867900
- Ticker: AMGN
- Trading venue: NASDAQ
- Price (as of 2026-06-25, 21:40): 352.82 USD
- Market cap: approximately 188 billion USD (as of late June 2026, based on recent NASDAQ data)
- Sector / industry: Health Care / Biotechnology
- Index membership: S&P 500, NASDAQ-100
- Next earnings date: not officially scheduled
This article was produced with AI assistance and editorially reviewed. Price and company figures without guarantee; prices and dates may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions carry risks up to and including total loss.
